GlassScriptPhysician profile
Adam Weston
NPI 1477729598
$11,556.64
in general payments reported to CMS, 2019-2025
24 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,511 · 2020: $1,219 · 2021: $1,730 · 2022: $1,569 · 2023: $1,952 · 2024: $1,930 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,304 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,303.67 |
| Education | $224.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,794.70 | 2019-2025 | Veklury |
| Viiv Healthcare Company | $1,693.71 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $1,660.77 | 2019-2025 | Dalvance, Teflaro, Avycaz |
| Merck Sharp & Dohme LLC | $940.30 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $790.32 | 2021-2025 | Nuzyra |
| Janssen Biotech, INC. | $776.13 | 2019-2023 | Symtuza |
| Insmed, INC. | $519.56 | 2019-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $295.12 | 2021-2025 | |
| Astellas Pharma US INC | $197.12 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $133.06 | 2019-2024 | Kimyrsa, Orbactiv, Rezzayo |
| Qiagen, LLC | $130.80 | 2019 | |
| Janssen Products, LP | $128.99 | 2019-2020 | |
| Allergan, INC. | $124.67 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $62.52 | 2025 | Vowst |
| Shionogi INC | $58.18 | 2025 | Fetroja |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $47.88 | 2021-2023 | Xerava |
| Dynavax Technologies Corporation | $40.83 | 2019-2023 | Heplisav-B |
| Janssen Scientific Affairs, LLC | $30.10 | 2020 | |
| Nabriva Therapeutics, Plc | $29.36 | 2021 | |
| Electromed, INC. | $28.94 | 2021-2022 | |
| Philips North America LLC | $23.54 | 2024 | (Ak6) Vest Therapy |
| Sanofi Pasteur INC. | $21.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2019 | |
| Theratechnologies INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.